Persistent Epithelial Defect Market is Anticipated to Witness Significant Growth by 2036 Driven by Rising Disease Burden and Emerging Regenerative Therapies | DelveInsight

Posted on
by

Persistent Epithelial Defect Market is Anticipated to Witness Significant Growth by 2036 Driven by Rising Disease Burden and Emerging Regenerative Therapies | DelveInsight
The Persistent Epithelial Defect (PED) Market is expected to experience substantial growth through 2036, fueled by increasing disease awareness, growing incidence of ocular surface disorders, unmet clinical needs, and the anticipated launch of innovative regenerative therapies. Emerging Persistent Epithelial Defect treatments such as OXERVATE (cenegermin) and ST266 are expected to transform the treatment landscape and contribute significantly to future market growth.

DelveInsight, a leading healthcare market research and consulting firm, has released its latest report, “Persistent Epithelial Defect (PED) Market Insights, Epidemiology, and Market Forecast – 2036.” The report provides a comprehensive understanding of Persistent Epithelial Defect epidemiology, market size, market trends, treatment landscape, emerging therapies, market share, and forecast across the United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan.

Key Takeaways from the Persistent Epithelial Defect Market

  • The Persistent Epithelial Defect market size across the 7MM is anticipated to grow significantly during the forecast period 2022–2036.

  • The United States accounted for the largest Persistent Epithelial Defect market share among the 7MM and is expected to maintain its dominance throughout the forecast period.

  • According to DelveInsight estimates, the total incident cases of Persistent Epithelial Defect in the 7MM were estimated to be more than 250,000 cases in 2025 and are expected to increase further through 2036.

  • The United States accounted for approximately 45% of total incident PED cases across the 7MM in 2025.

  • DelveInsight analysis indicates a male predominance in PED, with males accounting for more than 60% of total incident cases across the 7MM.

  • Within EU4 and the UK, Germany represented the highest number of incident cases, followed by France, reflecting a comparatively higher disease burden in these markets.

  • The Persistent Epithelial Defect treatment market currently relies heavily on supportive and procedure-based management approaches, creating significant opportunities for disease-modifying therapies.

  • Leading Persistent Epithelial Defect companies, including Dompe Farmaceutici, Noveome Biotherapeutics, and others, are actively developing novel therapies to address unmet treatment needs.

  • Promising Persistent Epithelial Defect therapies in development include OXERVATE (cenegermin) and ST266.

Keen to know more about the market? Request our sample page at:https://www.delveinsight.com/sample-request/persistent-epithelial-defect-market

Key Factors Driving the Persistent Epithelial Defect Market

Rising Incidence of Ocular Surface Disorders

The increasing prevalence of ocular diseases such as neurotrophic keratitis, dry eye disease, diabetes-related ocular complications, herpetic infections, and post-surgical corneal injuries continues to contribute to the growing burden of Persistent Epithelial Defect. This expanding patient population is expected to drive sustained market growth.

Significant Unmet Clinical Need

Current Persistent Epithelial Defect treatments primarily focus on supportive care, including artificial tears, sterile ocular ointments, bandage contact lenses, amniotic membrane transplantation, and surgical interventions. However, these approaches often fail to address the underlying biological mechanisms responsible for impaired corneal healing, creating demand for innovative therapies.

Advancements in Regenerative and Biologic Therapies

Growing research into ophthalmic biologics, regenerative medicine, epithelial healing agents, and cell-free biologic therapies is expected to transform the Persistent Epithelial Defect drug market. Emerging therapies are being designed to promote corneal regeneration, reduce inflammation, and restore epithelial integrity more effectively than current treatment options.

Persistent Epithelial Defect Competitive Landscape

The Persistent Epithelial Defect market remains largely underserved, with limited treatment options currently available. Existing management strategies rely heavily on supportive care and symptom control rather than active epithelial regeneration.

The emerging Persistent Epithelial Defect pipeline includes promising therapies such as OXERVATE (cenegermin) from Dompe Farmaceutici and ST266 from Noveome Biotherapeutics. These therapies are designed to promote corneal healing, epithelial regeneration, nerve restoration, and reduction of ocular inflammation, potentially addressing critical unmet needs in PED management.

The anticipated launch of these therapies is expected to significantly expand the Persistent Epithelial Defect treatment market and improve patient outcomes during the forecast period.

Discover more about therapies set to grab major Persistent Epithelial Defect market share @ Persistent Epithelial Defect Treatment Landscape

Recent Developments in the Persistent Epithelial Defect Market

  • OXERVATE (cenegermin) is currently being evaluated in a Phase III clinical study for the treatment of Persistent Corneal Epithelial Defect (PCED).

  • ST266, developed by Noveome Biotherapeutics, demonstrated positive results in a Phase II clinical trial evaluating its role in PED treatment.

  • Emerging research continues to focus on regenerative therapies, biologics, and epithelial healing agents designed to improve corneal restoration and reduce disease progression.

  • Increased funding opportunities and orphan disease recognition are encouraging further innovation and investment within the PED therapeutic landscape.

What is Persistent Epithelial Defect?

Persistent Epithelial Defect (PED), also known as Persistent Corneal Epithelial Defect (PCED), is a chronic ocular surface disorder characterized by the failure of corneal epithelial healing beyond 10–14 days. The condition results from impaired corneal regenerative capacity and is frequently associated with neurotrophic keratitis, dry eye disease, diabetes mellitus, herpetic infections, contact lens misuse, ocular surgeries, and eyelid abnormalities. If left untreated, PED may progress to corneal ulceration, stromal thinning, scarring, perforation, and vision impairment.

Persistent Epithelial Defect Epidemiology Segmentation

The Persistent Epithelial Defect epidemiology section provides insights into historical and forecasted patient populations across the 7MM and includes:

  • Total Incident Cases of Persistent Epithelial Defect

  • Gender-specific Incident Cases of Persistent Epithelial Defect

  • Etiology-specific Incident Cases of Persistent Epithelial Defect

  • Country-specific Incident Cases of Persistent Epithelial Defect

  • Treated Patient Population Analysis

Scope of the Persistent Epithelial Defect Market Report

  • Therapeutic Assessment: Persistent Epithelial Defect marketed and emerging therapies

  • Persistent Epithelial Defect Market Dynamics: Market drivers, barriers, opportunities, and future trends

  • Key Companies: Dompe Farmaceutici, Noveome Biotherapeutics, and others

  • Key Therapies: OXERVATE (cenegermin), ST266, and others

  • Competitive Intelligence Analysis: SWOT analysis, market positioning, and competitive benchmarking

  • Persistent Epithelial Defect Market Size, Market Share, Treatment Trends, and Forecast

  • KOL Views, Analyst Perspectives, Market Access, and Reimbursement Analysis

To know more about Persistent Epithelial Defect companies working in the treatment market, visit @ Persistent Epithelial Defect Clinical Trials and Therapeutic AssessmentTable of Contents

  • Persistent Epithelial Defect Market Report Introduction

  • Executive Summary of Persistent Epithelial Defect

  • Persistent Epithelial Defect Market Overview at a Glance

  • Disease Background and Overview

  • Causes and Risk Factors of Persistent Epithelial Defect

  • Signs and Symptoms

  • Diagnosis and Treatment Guidelines

  • Persistent Epithelial Defect Epidemiology and Patient Population

  • Country-Specific Epidemiology Analysis

  • Patient Journey Analysis

  • Persistent Epithelial Defect Current Treatment Practices

  • Persistent Epithelial Defect Unmet Needs

  • Persistent Epithelial Defect Emerging Therapies

  • OXERVATE (cenegermin): Clinical and Commercial Assessment

  • ST266: Clinical and Commercial Assessment

  • Persistent Epithelial Defect Competitive Landscape

  • Persistent Epithelial Defect Market Outlook

  • Country-Wise Persistent Epithelial Defect Market Analysis (2022–2036)

  • Market Size by Therapies Analysis

  • Market Access and Reimbursement

  • KOL Perspectives

  • SWOT Analysis

  • Appendix

  • Report Methodology

  • DelveInsight Capabilities

  • Disclaimer

  • About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical and biotechnology companies by providing comprehensive end-to-end solutions to improve business performance. DelveInsight offers actionable market intelligence, epidemiology forecasts, competitive landscape assessments, pipeline analysis, and strategic consulting services through its subscription-based healthcare intelligence platform, PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/